PO-02-204 COLCHICINE USAGE FOR PREVENTION OF POST ATRIAL FIBRILLATION ABLATION PERICARDITIS IN PATIENTS UNDERGOING HIGH POWER SHORT DURATION ABLATION

Radiofrequency ablation (RFA) for atrial fibrillation (AF) can be associated with up to 10% incidence of post-operative pericarditis, suspected more prevalent the advent high-power short duration (HPSD) ablation. This has led widespread use colchicine, an anti-inflammatory medication, prevention post-AF pericarditis. However, utility preventative colchicine remains unproven. To evaluate efficacy a routine regimen post-ablation pericarditis in patients (pts) undergoing HPSD AF. We retrospectively evaluated consecutive single-operator AF procedures at our institution from June 2019 July 2022. A protocol was introduced 2021 None pts before this date received while all after 0.6 mg twice daily 14 days starting on procedure day. Pts were divided into and non-colchicine groups (gps). recorded post chest pain, emergency room (ER) visit pericardial effusion, pericardiocentesis, any ER visit, hospitalization, recurrence cardioversion (CV) within first 30 post-ablation. also colchicine-related side effects medication compliance. Out 225 procedures, 20 excluded lack follow-up data, yielding 101 gp 104 gp. Both gps well-matched demographic procedural parameters (Table 1). There no significant difference pain (9.9% vs 8.6%, p = 0.7), effusion (2.9% 0.9%, 0.1), visits (11.9% 12.5%, 0.2), 30-day hospitalization (0.9% 0.96%,p 0.3) need CV (3.9 % 5.7%, 0.2) 15 had severe diarrhea, out which 12 discontinued it prematurely (Figure In retrospective analysis, not reduction or Colchicine usage diarrhea affecting patient Our findings argue against AF-ablation